Highly Specialised Services. Peritoneal Oncology Service. Report September 2015
|
|
- Melvin Blake
- 7 years ago
- Views:
Transcription
1 Highly Specialised Services Peritoneal Oncology Service Report September 2015 The Christie NHS Foundation Trust Wilmslow Road Withington Manchester M20 4BX
2 Contents Highly Specialised Services... 1 Introduction... 1 Staff... 3 Research and Education... 4 Patient and Public Engagement... 7 Activity... 8 Section 1: Referral Activity... 8 Section 2: Assessments and Treatment Quality Section 3: Length of stay, Op times and CC scores Section 4: Complications Section 5: Survival Appendices I Procedure Activity (Including Private Patients) Appendices II Outcomes Appendices III Outcomes by disease group Section IV ESSO Agenda... 26
3 Introduction Since its inception in 2002, the Peritoneal Oncology Service (POS) has grown from year to year. (p9 section 1 referrals Fig 1 and 2) More recently in we received 198 referrals (148 for appendiceal tumours and 50 for peritoneal metastases of colorectal origin (PMCR)). In this increased to 288 (186 appendix/ 102 PMCR); and from April 2015 we have received 169 referrals (112 Appendix/ 57 PMCR). Similarly the numbers of patients operated on have increased from 93 in to 145 in Since April 2015 we have already performed 78 procedures. In total, we have now performed 613 cytoreductions in appendiceal tumours and 151 such procedures in patients with PMCR (Fig 1, 2). We have prospectively monitored outcomes and have low mortality and complication rates alongside internationally comparable survival, details of which are outlined in this report. Due to the expansion of the service we have increased the workforce to support patient flow. Mr Omer Aziz was appointed in May 2014 as the 6 th consultant surgeon. His expertise in laparoscopic surgery has augmented the existing team and has allowed us to expand our minimal access service for peritoneal tumours. Mr Selvasekar and Mr Aziz have now performed 36 laparoscopic cytoreductions and HIPEC for patients with low volume, early stage disease which represents the largest cohort of patients worldwide undergoing this technique. Scott Brown and Margaret Butler joined us in July 2013 and July 2014 respectively as two additional Clinical Nurse Specialists to complement Rebecca Halstead s experience in this role. The 3 CNS s cover the entire unit s activities and provide a vital support mechanism to the patients. They are the organisational force behind the now weekly Multi-Disciplinary Team meetings and the patients investigations and clinic visits. In addition, Rebecca Halstead not only runs the telephone follow-up service but also performs her own Nurse-led telephone clinic for patients on watch and wait surveillance and for those who are post 5 years follow-up. Grant Punnett was appointed as the Unit s Data Manager in June 2013 and is responsible for the upkeep of the prospective database started in 2002 and organises the quarterly morbidity and mortality meetings. With regard to our perfusion service, we now have 4 trained perfusion practitioners who can all provide HIPEC independently with Rachel Aziz heading this group as the HIPEC service manager. We replaced our 2 older perfusion machines this year with 3 new Rand machines to ensure that we are using the most modern equipment adding to our training capabilities in this field. As recognition of the work of the unit in the area of PMCR, we were awarded Cancer Care Team of the Year by the British Medical Journal Group and MacMillan in May Our academic profile has been recognised with the appointment of Andrew Renehan as Professor of Cancer Studies and Surgery, University of Manchester in June 2013 and Sarah O Dwyer as Clinical Professor of Surgery, University of Manchester in July The report outlines the continued efforts of the team in exploring new approaches to evaluation of current and novel treatments (p4) In October 2015 we hosted the first UK course and Advanced Workshop on Peritoneal Surface Malignancy in conjunction with the European Society of Surgical Oncology (ESSO). The course attracted faculty from 10 countries and delegates from 17 countries as far as Canada and Australia. The content included Keynote addresses, lectures, a mock MDT, video based education and live operating sessions (appendix V). Our links with ESSO has inaugurated the unit as a recognised European training centre for Fellowships 1
4 in peritoneal malignancy: we currently have two registered fellows on this programme one from Greece and one from Jordan. We have recently finished redesigning and producing our website which sits within the Christie s site. This now contains up to date information for clinicians and patients. It contains a google map to assist the patient and their family with a virtual tour through the department and videos including examples of patient experiences of the service; a wide range of content is available at With regard to the future, we have recently submitted a business plan to accommodate the development of the peritoneal service in tune with NHS England commissioning for PMCR. This includes the appointment of a dedicated service manager, an additional CNS and Consultant Surgeon. Sarah O Dwyer continues to advise the Clinical Reference Group for Specialised Colorectal Services in regard to peritoneal malignancy. In 2013 she became Chair of the Peritoneal Surface Maligancy Sub Committee for The Association of Coloproctology of Great Britain and Ireland. The committee meets 2-3 times each year to achieve clinical consensus for the management of these conditions. Through this group the potential expansion of treatment centres for colorectal peritoneal metastases and Commissioning through evaluation for mesothelioma is being discussed. In his role of Clinical Lead for the Interventional Procedure Unit, Malcolm Wilson is leading the 7.6m development of day-case services in the trust. It is anticipated that this project will commence in February 2016 to be operational by April This will free up operating theatre and outpatient facilities to allow further expansion of the POS alongside other surgical activities in the Trust. Malcolm Wilson MD FRCS October
5 Staff Name Prof ST O Dwyer Mr MS Wilson Mr PE Fulford Prof AG Renehan Mr CR Selvasekar Mr O Aziz Mr R Deshpande Dr MP Saunders Dr R Kochhar Dr V Kasipandian Dr B Chakrabarty Rebecca Halstead Margaret Butler Scott Brown Rachel Aziz Nancy Flynn-Chadwick Andy Colclough Rachelle Wood Grant Punnett Rosanne Meronti Job Title Consultant Surgeon/Lead Clinician Consultant Surgeon Consultant Surgeon Professor in Cancer Studies and Surgery, Honorary Consultant Consultant Surgeon Consultant Surgeon Consultant Hepatobiliary Surgeon Consultant Oncologist Lead Consultant Radiologist Lead Consultant Anaesthetist Lead Consultant Histopathologist Clinical Nurse Specialist Clinical Nurse Specialist Clinical Nurse Specialist HIPEC Service Manager HIPEC Perfusionist HIPEC Perfusionist HIPEC Perfusionist Data Manager MDT Co-ordinator 3
6 Research and Education The research activities continue along two broad work streams: clinical studies and trials; and basic science research. In 2014/2015, from our prospective clinical databases, we presented data in five abstracts at the Peritoneal Surface Oncology Group International (PSOGI), Amsterdam, October 2014; and two abstracts at the Digestive Disease Federation Conference, London, June We led on two publications during this period one as a letter in the Journal of Clinical Oncology on the evolution of treatment of peritoneal tumour treatment (lead: Professor O Dwyer) (1); and one as a first paper on the use of laparoscopic cytoreductive surgery in the setting of risk reducing treatment in very early appendiceal mucinous tumours (lead: Mr Selvasekar) (2). Importantly, during this period, we were awarded funding from the Bowel Disease Research Foundation to fund a prospective project titled Development of an IDEAL framework to standardise the complex intervention of cytoreductive surgery for colorectal peritoneal metastases: a necessary step to phase III trials (lead: Professor Renehan). This is a combined project with the Basingstoke Peritoneal Malignancy Institute, which will start in January In 2014, we finished a decade long collaboration in Pseudomyxoma Peritonei (PMP) basic science research with the retirement of Professor Peter Stern at the Cancer Research UK Manchester Institute, CRUK MI (on the Christie campus). At its completion, we published a first in the world paper on the immortalisation of PMP cell lines (3). We are now establishing a new collaboration with Dr John Brognard, in CRUK MI, taking forward this work with laboratory studies on gene expression and their mechanisms in PMP, using the novel PMP cell lines (lead: Professor Renehan). Involvement in two international research activities is noteworthy. 1), Manchester is part of a European Horizon (H2020) programme grant application, known as Cure4PM: lead Professor Renehan. 2), Manchester is part of the International Rare Cancer Initiative (IRCI) in peritoneal malignancies (leads Professor Renehan, Dr Saunders). From an educational perspective the team has been active internationally In 2013 we were central to the First INDO-UK Oncology Summit in Chennai, India. Lectures and workshops were run by the POS team in conjunction with The Christie School of Oncology. In 2014 Mr Selvasekar co-ordinated a two day programme specifically dealing with POS which included a joint MDT by teleconference with the Chennai team and a demonstration operating session transmitted live to the auditorium in Chennai. The team have given a number of lectures and presentations and hosted visiting surgeons and trainees from India, Egypt, Germany and Jordan Publications : References 1. O'Dwyer S, Verwaal VJ, Sugarbaker PH. Evolution of Treatments for Peritoneal Metastases From Colorectal Cancer. J Clin Oncol 2015;33(18): Fish R, Selvasekar C, Crichton P, Wilson M, Fulford P, Renehan A, et al. Risk-reducing laparoscopic cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for low-grade appendiceal mucinous neoplasm: early outcomes and technique. Surg Endosc 2014;28(1):
7 3. Roberts DL, O'Dwyer ST, Stern PL, Renehan AG. Global gene expression in pseudomyxoma peritonei, with parallel development of two immortalized cell lines. Oncotarget 2015;6(13): Appendiceal Goblet Cell Carcinoids: Management Considerations from a Reference Peritoneal Tumour Service Centre and ENETS Centre of Excellence Neuroendocrinology Oct 2015 (DOI: / ) Posters Minimal Access Cytoreductive Surgery and Hyperthermic intraperitoneal chemotherapy for at risk low-grade appendiceal mucinous neoplasms: 3 year experience. Peritoneal Oncology Surface Malignancies Summit: 9-11 October 2014 Elective 2-stage cytoreduction and hyperthermic intraperitoneal chemotherapy in selected patients with widespread, high volume pseudomyxoma peritonei. Peritoneal Oncology Surface Malignancies Summit: 9-11 October 2014 Clinico-pathological classification of mucinous neoplasms of appendiceal origin combining primary lesion and disseminated features. Peritoneal Oncology Surface Malignancies Summit: 9-11 October 2014 Dysregulated Wnt and Notch Pathways at Gene and Protein Levels in Pseudomyxoma Peritonei. Peritoneal Oncology Surface Malignancies Summit: 9-11 October 2014 Presentations North Manchester Hospital FRCS course, January 2013 HIPEC and how it works INDO-UK Oncology Summit, Chennai, Sept 2013 Cytoreduction and HIPEC Postoperative management and complications How to publish a research paper Improving outcomes in peritoneal metastases from colon cancer Peritoneal Oncology Surface Malignancies Summit, Amsterdam, October 2014 Clinico-Pathologic Study of Goblet Cell Carcinoid of the Appendix and outcomes following Cytoreductive surgery and Hyperthermic Intra-peritoneal Chemotherapy. International Guidelines for management of peritoneal surface malignancy Peritoneal Disease Chennai, India, November 2014 Primary peritoneal cancer live operating The role of the CNS in a peritoneal service The Peritoneal Service MDT Setting up a peritoneal Service 5
8 International Guidelines for peritoneal malignancy Peritoneal Disease Workshop Basingstoke, December 2014 Peritoneal Metastases in colorectal cancer European developments in Peritoneal Maligancy Surgical management of appendiceal carcinoid tumours MAHSC Conference Manchester January 2015 Telephone follow up for a national peritoneal service Nottingham Cancer Network, August 2015 Peritoneal Metastases in colorectal cancer. Chemotherapy in the management of PMP ESSO Advanced Course in Peritoneal Malignancy, Manchester October, 2015 Nutrition and enhanced recovery in PSM Standardised recording of mortality and morbidity Surgical techniques : RUQ, MAS Presentation and outcomes of appendiceal neoplasia 6
9 Patient and Public Engagement A patient survivorship group has been generated following requests from patients and their families. In December 2015 the first formal meeting will take place supported by the Clinical Nurse Specialists Rebecca Halstead and Margaret Butler. This will be aimed at patients within the Peritoneal Tumour Service and will allow opportunities to meet one another/support each other, ask the team questions and engage with the complimentary therapies team. The expectation is to have an annual Afternoon Tea and meeting with an agenda led by the patients themselves. Over the last 18 months there have been a number of events hosted by patients and their families including, coffee mornings, a bake off and a vintage tea party. Whilst these events raise money donated to the PMP research and patient support fund they also allow fellowship, support and camaraderie. The redesign of the Web site was centred around improving access for patient and families to a virtual tour of the facilities that they are likely to come across through their patient journey. We have included video vignettes of patient experiences to help demystify the treatments of these rare conditions. We will be undertaking a service user experience survey in 2016 which will include patients/families/ supporters and professionals to identify areas for improvements 7
10 Activity Section 1: Referral Activity Specialist Commissioning (Appendix) Referrals Q30 - NORTH EAST Q31 - NORTH WEST Q32 - YORKSHIRE & THE HUMBER Q33 - EAST MIDLANDS Q34 - WEST MIDLANDS Q35 - EAST OF ENGLAND Q36 - LONDON Q37 - SOUTH EAST COAST Q38 - SOUTH CENTRAL Q39 - SOUTH WEST ENGLAND - NOT KNOWN W01 - WALES NORTHERN IRELAND SCOTLAND OTHER GB OTHER TOTAL PMCR Referrals Q30 - NORTH EAST Q31 - NORTH WEST Q32 - YORKSHIRE & THE HUMBER Q33 - EAST MIDLANDS Q34 - WEST MIDLANDS Q35 - EAST OF ENGLAND Q36 - LONDON Q37 - SOUTH EAST COAST Q38 - SOUTH CENTRAL Q39 - SOUTH WEST ENGLAND - NOT KNOWN W01 - WALES NORTHERN IRELAND SCOTLAND OTHER GB OTHER TOTAL
11 UK distribution of Specialist Commissioning (Appendix) Referrals UK distribution of PMCR referrals 9
12 Specialist Commissioning (Appendix) Demographics Age Median - Male: Median - Female: Range: N = Gender Male Female Total PMCR Demographics Age Median - Male: Median - Female: Range: N = Gender Male Female Total
13 Section 2: Assessments and Treatment Figure 1: Appendix tumours Cases and Operations Source data in Appendices I Figure 2: PMCR - Cases and Operations Source data in Appendices I 11
14 Specialist Commissioning (Appendix) Assessment/Follow Up Activity (Q1 & Q2) First Assessment IP First Assessment OP Re Assessment IP Re Assessment OP Follow Ups Telephone Follow Ups Chemo Appointments Total PMCR Assessment/Follow Up Activity (Q1 & Q2) First Assessment IP First Assessment OP Re Assessment IP Re Assessment OP Follow Ups Chemo Appointments Total
15 Quality Section 3: Length of stay, Op times and CC scores. Operation times Cytoreduction Major Debulk Median Op Time Range Op Time Median Op Time Range Op Time (Q1 & Q2) Hospital Stay Level 2 CCU Stay Level 2 Level 2 Level 2 Level 2 Total CCU Total CCU Total CCU Total CCU Stay Stay Stay Stay Stay Stay Stay Stay Total Stay (Q1 & Q2) Level 2 CCU Total Stay Stay Median Range
16 CC Scores All cases Source data in Appendices II CC Scores Appendix tumours Source data in Appendices III CC Scores PMCR Source data in Appendices III 14
17 Section 4: Complications Complications Unit Overview (to April 2015, n = 726) n % No Complications Minor Complications (NCI grade 1-2) Major Complications (NCI grade 3-4) Peri-Operative (30 Day) Mortality Complications Appendix Pathologies Overview (to April 2015, n = 562) n % No Complications Minor Complications (NCI grade 1-2) Major Complications (NCI grade 3-4) Peri-Operative (30 Day) Mortality Complications PMCR Overview (to April 2015, n = 125) n % No Complications Minor Complications (NCI grade 1-2) Major Complications (NCI grade 3-4) Peri-Operative (30 Day) Mortality
18 Complication rates for past 5 years Minor Complications* Major Complications** Peri-Operative (30 Day) Mortality Cases n % n % n % Total * Defined as Grade 1 or 2 NCI Common Terminology Criteria for Adverse Events (v4.0) ** Defined as Grade 3 or 4 NCI Common Terminology Criteria for Adverse Events (v4.0) Laparoscopic Cytoreduction & HIPEC - overview Cases Median Hospital Stay Median CCU Stay Median PCI Score PCI Range Median Op Time (Q1 & Q2) Total Laparoscopic Cytoreduction & HIPEC Complications n % No Complications Minor Complications (NCI grade 1-2) Major Complications (NCI grade 3-4) Peri Operative (30 Day) Death
19 0 Survival (%) Survival (%) Service Report September 2015 Section 5: Survival PMP Survival - Cytoreduction Vs Debulk Cytoreduction +/- HIPEC Debulking Procedure Time (Months) Number at risk Cytoreduction +/- HIPEC Debulking Procedure Appendix Ca - Cytoreduction Vs Debulk Cytoreduction +/- HIPEC Debulking Procedure Number at risk Cytoreduction +/- HIPEC Debulking Procedure Time (Months)
20 0 Survival (%) Service Report September 2015 PMCR Survival - Cytoreduction Vs Debulk Cytoreduction +/- HIPEC Debulking Procedure Time (Months) Number at risk Cytoreduction +/- HIPEC Debulking Procedure
21 Appendices I Procedure Activity (Including Private Patients) All Procedure Activity by year Major Debulk Cytoreduction Total (Q1 & Q2) Total Appendix Procedure Activity by year Undergone Cyto/Debulk Confirmed Cases (6 months) Total
22 PMCR Procedure Activity by year Undergone Cyto/Debulks Confirmed Cases (6 months) Total
23 Appendices II Outcomes All n % Patients 1759 Undergone Cyto/Debulk Cytoreduction & HIPEC Debulking Procedure Total Procedures 804 PCI Median 12 PCI Range 0-39 CC0 Count CC1 Count CC2 Count CC3 Count CC Score Missing
24 Appendices III Outcomes by disease group PMP n % Patients 584 Undergone Cyto/Debulk Cytoreduction & HIPEC Debulking Procedure Total Procedures 384 PCI Median 20 PCI Range 0-39 CC0 Count CC1 Count CC2 Count CC3 Count CC Score Missing PMCR n % Patients 374 Undergone Cyto/Debulk Cytoreduction & HIPEC Debulking Procedure Total Procedures 151 PCI Median 8 PCI Range 0-39 CC0 Count CC1 Count CC2 Count CC3 Count CC Score Missing
25 LAMN 2 n % Patients 129 Undergone Cyto/Debulk Cytoreduction & HIPEC Debulking Procedure Total Procedures 63 PCI Median 0 PCI Range 0-15 CC0 Count CC1 Count CC2 Count CC3 Count CC Score Missing Appendix Adenocarcinoma (incl MCP - High n % Grade) Patients 224 Undergone Cyto/Debulk Cytoreduction & HIPEC Debulking Procedure Total Procedures 125 PCI Median 9 PCI Range 0-39 CC0 Count CC1 Count CC2 Count 10 8 CC3 Count CC Score Missing
26 LAMN 1 n % Patients 93 Undergone Cyto/Debulk Cytoreduction & HIPEC 4 80 Debulking Procedure 0 20 Total Procedures 4 PCI Median 20 PCI Range Mar-16 CC0 Count CC1 Count 0 0 CC2 Count 0 0 CC3 Count 0 0 CC Score Missing 0 0 Adenocarcinoma ex Goblet Cell Carcinoid n % Patients 33 Undergone Cyto/Debulk Cytoreduction & HIPEC Debulking Procedure 1 5 Total Procedures 20 PCI Median 6 PCI Range 0-26 CC0 Count CC1 Count 2 10 CC2 Count 3 15 CC3 Count 1 5 CC Score Missing
27 Goblet Cell Carcinoid n % Patients 32 Undergone Cyto/Debulk Cytoreduction & HIPEC Debulking Procedure Total Procedures 17 PCI Median 1 PCI Range 0-9 CC0 Count CC1 Count 0 0 CC2 Count 0 0 CC3 Count 0 0 CC Score Missing Others n % Patients 278 Undergone Cyto/Debulk Cytoreduction & HIPEC Debulking Procedure Total Procedures 40 PCI Median 11 PCI Range 0-39 CC0 Count CC1 Count CC2 Count CC3 Count 6 15 CC Score Missing
28 Section IV ESSO Agenda Programme Peritoneal_Manchester final WORD - rb.pdf 27
ESSO Course on Peritoneal Surface Malignancy
ESSO Course on Peritoneal Surface Malignancy In partnership with The Christie School of Oncology 08-09 October 2015 MANCHESTER (UK) ESSO Course on Peritoneal Surface Malignancy Chair: Sarah O Dwyer, The
More informationPeritoneal Surface Malignancies. Ira Allen Jacobs, MD, FACS Surgical Oncology San Diego, CA
Peritoneal Surface Malignancies Ira Allen Jacobs, MD, FACS Surgical Oncology San Diego, CA Cancer dissemination routes Hematogenous metastases Lymphatic metastases Implants on peritoneal surfaces Surgically
More informationCytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC): Now and the Future
Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC): Now and the Future Mazin Al-kasspooles, MD Associate Professor of Surgery Division of Surgical Oncology Director, Regional Therapy
More informationCorporate Medical Policy
Corporate Medical Policy Hyperthermic Intraperitoneal Chemotherapy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hyperthermic_intraperitoneal_chemotherapy 5/19/2005 3/2016 3/2017
More informationCytoreduction and hyperthermic intraperitoneal chemotherapy for the treatment of pseudomyxoma
Medical Policy Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Pseudomyxoma Peritonei and Peritoneal Carcinomatosis of Gastrointestinal Origin, and Peritoneal Mesothelioma
More informationNational Bowel Cancer Audit Report 2008 Public and Executive Summary
National Bowel Cancer Audit Report 2008 Public and Executive Summary Prepared in association with: Healthcare Quality Improvement Partnership HQIP Association of Coloproctology of Great Britain and Ireland
More information2nd International Symposium on Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC)
2nd International Symposium on Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) Wednesday Oct 7th, 2015 Congress Center (Hörsaal 1 3) Marien Hospital Herne Accreditation by the Medical Chamber
More informationLuis D. Carcorze Soto, MD PGY-3
Luis D. Carcorze Soto, MD PGY-3 Peritoneal Surface Malignancies Peritoneum Patient Selection Operative Technique HIPEC EPIC Primary: Primary Peritoneal Carcinoma Malignant Peritoneal Mesothelioma Metastatic:
More informationIntraoperative Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Volodymyr Labinskyy MD
Intraoperative Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Volodymyr Labinskyy MD KCHC 8/29/13 52 y.o. F presented with severe pain in the right back and right flank, sharp, 8 out of 10, for 7 days.
More informationCOMMISSIONING. for ULTRA-RADICAL SURGERY ADVANCED OVARIAN CANCER
COMMISSIONING for ULTRA-RADICAL SURGERY in ADVANCED OVARIAN CANCER WHY THIS MUST HAPPEN PERSPECTIVE COMMISSIONING FOR WHO, FOR WHAT? Biological Basis Surgical Basis International and national standards
More informationCytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis in the elderly
Huang et al. World Journal of Surgical Oncology (2015) 13:262 DOI 10.1186/s12957-015-0682-7 WORLD JOURNAL OF SURGICAL ONCOLOGY RESEARCH Cytoreductive surgery and perioperative intraperitoneal chemotherapy
More informationHow To Treat Mesothelioma
Mesothelioma in the UK Liz Darlison Mesothelioma UK The National Macmillan Mesothelioma Resource Centre June 2010 Mesothelioma Applied Research Foundation - 2010 www.curemeso.org Contents Size of Mesothelioma
More informationRachel E. Kirby, Jing Zhao, Terence Chua, Winston Liauw and David L. Morris *
Send Orders for Reprints to reprints@benthamscience.net The Open Surgical Oncology Journal, 2014, 5, 1-5 1 Open Access Avoidance of Early Post-Operative Intraperitoneal Chemotherapy (EPIC) Following Peritonectomy
More informationINTRAPERITONEAL HYPERTHERMIC CHEMOTHERAPY (IPHC) FOR PERITONEAL CARCINOMATOSIS AND MALIGNANT ASCITES. INFORMATION FOR PATIENTS AND FAMILY MEMBERS
INTRAPERITONEAL HYPERTHERMIC CHEMOTHERAPY (IPHC) FOR PERITONEAL CARCINOMATOSIS AND MALIGNANT ASCITES. INFORMATION FOR PATIENTS AND FAMILY MEMBERS Description of Treatment A major difficulty in treating
More informationPseudomyxoma Peritonei Where are we in 2014?
Pseudomyxoma Peritonei Where are we in 2014? Santiago González-Moreno, MD, PhD Head, Department of GI Surgical Oncology Peritoneal Surface Oncology Program Medical Director * * * * * * * * * * * * French
More informationDivision of Cancer Surgery Information Guide
Division of Cancer Surgery Information Guide Professor Sandy Heriot Director - Division Cancer Surgery Professor Michael Henderson Deputy Director Division Cancer Surgery Executive Sponsor Education and
More informationINTRAOPERATIVE HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY (HIPEC)
MEDICAL POLICY INTRAOPERATIVE HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY (HIPEC) Policy Number: CS141.A Effective Date: September 1, 2015 Table of Contents COVERAGE RATIONALE DEFINITIONS... APPLICABLE CODES..
More informationBritish Thoracic Oncology Group (BTOG) Annual Report - April 2014 to March 2015
0116 250 2811 dawn.mckinley@uhl-tr.nhs.uk www.btog.org @BTOGORG British Thoracic Oncology Group (BTOG) Annual Report - April 2014 to March 2015 BTOG s Aim BTOG is the multi-disciplinary group for professionals
More informationBOWEL CANCER. The doctor has explained that you have a growth or tumour, in your bowel or rectum and could be cancer.
Patient and Carer Information BOWEL CANCER Please read this leaflet carefully. It is important that you take note of any instructions or advice given. If you have any questions or problems that are not
More informationThe Role of the MDT Coordinator. Laura Throssell
The Role of the MDT Coordinator Laura Throssell NHS Cancer Plan (2000) the care of all patients with cancer should be formally reviewed by a specialist team. all patients have the benefit of the range
More informationPopulation Pharmacokinetics and Pharmacodynamics of Cisplatinum During Intraperitoneal Chemohyperthermia Using a Closed Abdominal Procedure
Population Pharmacokinetics and Pharmacodynamics of Cisplatinum During Intraperitoneal Chemohyperthermia Using a Closed Abdominal Procedure Eddy Cotte, Brigitte Tranchand, Annie-Claude Beaujard, François-Noël
More informationThe East Midlands Mesothelioma Multi-disciplinary Team (MDT) Cancer Services Information for Patients
The East Midlands Mesothelioma Multi-disciplinary Team (MDT) Cancer Services Information for Patients i Introduction The team of health professionals looking after you is known as the multidisciplinary
More informationBritish Cardiovascular Society: Guidance on appropriate workload for consultant cardiologists
Page 1 of 9 British Cardiovascular Society: Guidance on appropriate workload for consultant cardiologists David Hackett Vice-President, Clinical Standards Division March 2010 Introduction: The British
More informationSouth Eastern Health and Social Care Trust
South Eastern Health and Social Care Trust JOB DESCRIPTION TITLE OF POST: Consultant General Surgeon LOCATION: This post is part of the South Eastern Trust and will be based at the Ulster Hospital. However,
More informationThis document contains four General Surgery placement descriptions:
This document contains four General Surgery descriptions: North Central Thames Foundation School Individual Placement Description - Basildon and Thurrock University Hospitals NHS Foundation Trust Placement
More informationBetter bowel cancer care in Scotland
Better bowel cancer care in Scotland October 2013 Page 1 of 27 Contents Table of Figures 3 Foreword 4 Executive summary and recommendations 5 Introduction 7 Incidence, mortality and survival rates for
More informationGuidance notes for commissioners implementing the policy on Complex endovascular stent grafts in the management of abdominal aortic aneurysm
Guidance notes for commissioners implementing the policy on Complex endovascular stent grafts in the management of abdominal aortic aneurysm NHSCB/A04/P/a NHS England: Guidance notes for commissioners
More informationSix Month Pilot Analysis: Improving Rehabilitation for Men with Prostate Cancer in North East London
Six Month Pilot Analysis: Improving Rehabilitation for Men with Prostate Cancer in North East London June 2015 Helen Whitney (Physiotherapist and Prostate Cancer Project Lead) Thufayel Islam (Prostate
More informationOSSANZ Recognised Post-fellowship Posts Bariatric Surgery
OSSANZ Recognised Post-fellowship Posts Bariatric Surgery Executive Summary The need for post-fellowship sub-specialty training in General Surgery has been recognised by the profession and has led to the
More informationHip replacements: Getting it right first time
Report by the Comptroller and Auditor General NHS Executive Hip replacements: Getting it right first time Ordered by the House of Commons to be printed 17 April 2000 LONDON: The Stationery Office 0.00
More informationLiver Resection. Patient Information Booklet. Delivering the best in care. UHB is a no smoking Trust
Liver Resection Patient Information Booklet Delivering the best in care UHB is a no smoking Trust To see all of our current patient information leaflets please visit www.uhb.nhs.uk/patient-information-leaflets.htm
More informationLung Cancer Multidisciplinary Meeting Toolkit. National Lung Cancer Working Group
Lung Cancer Multidisciplinary Meeting Toolkit National Lung Cancer Working Group September 2014 Contents Introduction 1 Multidisciplinary meetings 1 Toolkit for implementing high-quality lung cancer MDMs
More informationThis document contains three General Surgery placement descriptions:
This document contains three General Surgery descriptions: North Central Thames Foundation School (NCTFS) Individual Description - Basildon and Thurrock University Hospitals NHS Foundation Trust type of
More informationNational Clinical Programme in Surgery (NCPS) Care Pathway for the Management of Day Case Laparoscopic Cholecystectomy
National Clinical Programme in Surgery (NCPS) Care Pathway for the Management of Day Case Consultant Surgeon DRAFT VERSION 0.5 090415 Table of Contents 1.0 Purpose... 3 2.0 Scope... 3 3.0 Responsibility...
More informationGUIDELINES FOR ASSESSMENT OF SPINAL STABILITY THE CHRISTIE, GREATER MANCHESTER & CHESHIRE. CP57 Version: V3
GUIDELINES FOR ASSESSMENT OF SPINAL STABILITY THE CHRISTIE, GREATER MANCHESTER & CHESHIRE Procedure Reference: Document Owner: CP57 Version: V3 Dr V. Misra Accountable Committee: Acute Oncology Group Network
More informationColumbia University Mesothelioma Applied Research Foundation - 2009 - www.curemeso.org. Mesothelioma Center www.mesocenter.org
Columbia University Mesothelioma Center www.mesocenter.org Multimodal clinical trials, treatment (surgery, radiation, chemotherapy) Peritoneal mesothelioma program Immunotherapy translational, experimental
More informationTHE AUSTRALIAN MESOTHELIOMA REGISTRY (AMR)
THE AUSTRALIAN MESOTHELIOMA REGISTRY (AMR) Professor Nico van Zandwijk Director Asbestos Diseases Research Institute US US UK UK COUNTRY NZ CAN COUNTRY NZ CAN AUS AUS Mesothelioma International context
More informationThere must be an appropriate administrative structure for each residency program.
Specific Standards of Accreditation for Residency Programs in Radiation Oncology 2015 VERSION 3.0 INTRODUCTION The purpose of this document is to provide program directors and surveyors with an interpretation
More informationQuality in Nursing Clinical Nurse Specialists in Cancer Care; Provision, Proportion and Performance
Ensuring Better Treatment National Cancer Action Team Part of the National Cancer Programme Quality in Nursing Clinical Nurse Specialists in Cancer Care; Provision, Proportion and Performance A census
More informationFinding out about vehicle maintenance and repair
Finding out about vehicle maintenance and repair The vehicle maintenance and repair industry is part of the automotive retail sector, represented by the IMI Automotive Sector Skills Council, which also
More informationFocussing on Inequalities: Variation in breast cancer outcomes with age and deprivation
Focussing on Inequalities: Variation in breast cancer outcomes with age and deprivation West Midlands Cancer Intelligence Unit ACKNOWLEDGEMENTS ACKNOWLEDGEMENTS Acknowledgements ACKNOWLEDGEMENTS The authors
More informationCANCERS OF THE PERITONEUM PERITONEAL MESOTHELIOMA PREFERRED MODEL OF CARE AND CRITERIA FOR REFERENCE CENTRES
CANCERS OF THE PERITONEUM PERITONEAL MESOTHELIOMA PREFERRED MODEL OF CARE AND CRITERIA FOR REFERENCE CENTRES Coordinator: Alex Kartheuser (Colorectal Surgery, Cliniques universitaires St-Luc, UCL) Authors
More informationPOLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER CODING INFORMATION REFERENCES POLICY HISTORY
Original Issue Date (Created): July 1, 2002 Most Recent Review Date (Revised): July 22, 2014 Effective Date: October 1, 2014 POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT
More informationCaring for Vulnerable Babies: The reorganisation of neonatal services in England
Caring for Vulnerable Babies: The reorganisation of neonatal services in England LONDON: The Stationery Office 13.90 Ordered by the House of Commons to be printed on 17 December 2007 REPORT BY THE COMPTROLLER
More informationHow To Prepare A Meeting For A Health Care Conference
THORACIC ONCOLOGY MULTIDISCIPLINARY TEAM MEETINGS: OPERATIONAL POLICY EXECUTIVE SUMMARY 1. All patients in Lothian with thoracic malignancies should be discussed at designated times in pathway (see App
More informationManagement of Peritoneal Metastases (PM) from colorectal cancers: New Perspectives. Dominique ELIAS
Management of Peritoneal Metastases (PM) from colorectal cancers: New Perspectives Dominique ELIAS Declaration of interest BOARDS Congress and teaching 0 Merck 0 Ipsen Novartis Sanofi Trials The peritoneum
More informationSpecialist adult cancer nurses in England
Specialist adult cancer nurses in England A census of the specialist adult cancer nursing workforce in the UK, 2014 2 Contents Foreword 4 1. Introduction 6 1.1 Background 6 1.2 Methods 7 1.3 Selection
More informationA succesfull case of HIPEC in a peritoneal mesothelioma patient
A succesfull case of HIPEC in a peritoneal mesothelioma patient Firmino, NLJ¹²; Miranda, E¹³; Oliveira, DA ²; Lima, MBA ¹²; Diniz, AF ¹²; Gomes, GES ¹²; Azevedo, LW ¹²; Soares,MC¹²; Gomes, ASA³. ¹Pernambuco
More informationGynaecological Cancers 2015
Gynaecological Cancers 2015 Annex D Epidemiology 1. It is estimated that there will be an increase in the incidence of gynaecological cancers by 2015. For example: a. The incidence of cervical cancer is
More informationImproving healthcare for people with long-term conditions
Improving healthcare for people with long-term conditions UWe-book: Number Two 1 Health and Well-being At UWE our research and development is real and dynamic, identifying problems and providing solutions
More informationCOST OF SKIN CANCER IN ENGLAND MORRIS, S., COX, B., AND BOSANQUET, N.
ISSN 1744-6783 COST OF SKIN CANCER IN ENGLAND MORRIS, S., COX, B., AND BOSANQUET, N. Tanaka Business School Discussion Papers: TBS/DP05/39 London: Tanaka Business School, 2005 1 Cost of skin cancer in
More informationH. Richard Alexander, Jr., M.D. Department of Surgery and The Greenebaum Cancer Center University of Maryland School of Medicine Baltimore, Md
Major Advances in Cancer Prevention, Diagnosis and Treatment~ Why Mesothelioma Leads the Way H. Richard Alexander, Jr., M.D. Department of Surgery and The Greenebaum Cancer Center University of Maryland
More informationThis vision does not represent government policy but provides useful insight into how breast cancer services might develop over the next 5 years
Breast Cancer 2015 Annex C Background 1. Breast cancer is the most common cancer in women in England with (not including cases of ductal carcinoma in situ (DCIS) 1 ) 39,681 new cases diagnosed in 2008
More information15th Colorectal Day Programme
15th Colorectal Day Programme 7TH OF JUNE 2016 AARHUS UNIVERSITY HOSPITAL, SKEJBY ENTRANCE 6, AUDITORIUM A www.crd.auh.dk Fotograf: Kristian Bang, AUH Dear friends and colleagues It is our pleasure to
More informationSalisbury Lung Cancer Service (1 of 5)
Salisbury Lung Cancer Service (1 of 5) i If you need this information in another language or medium (audio, large print, etc) please contact Customer Care on 0800 374 208 email: customercare@ salisbury.nhs.uk.
More informationL Lang-Lazdunski, A Bille, S Marshall, R Lal, D Landau, J Spicer
Pleurectomy/decortication, hyperthermic pleural lavage with povidone-iodine and systemic chemotherapy in malignant pleural mesothelioma. A 10-year experience. L Lang-Lazdunski, A Bille, S Marshall, R Lal,
More informationThe Whipple Operation for Pancreatic Cancer: Optimism vs. Reality. Franklin Wright UCHSC Department of Surgery Grand Rounds September 11, 2006
The Whipple Operation for Pancreatic Cancer: Optimism vs. Reality Franklin Wright UCHSC Department of Surgery Grand Rounds September 11, 2006 Overview Pancreatic ductal adenocarcinoma Pancreaticoduodenectomy
More informationImproving access to insulin pump therapy: The role of the Insulin Pump Network
Article Improving access to insulin pump therapy: The role of the Insulin Pump Network Peter Hammond Citation: Hammond, P (2013) Improving access to insulin pump therapy: The role of the Insulin Pump Network.
More informationGuide for families with children receiving Proton Beam Therapy abroad
Xxxxxxxxxxxxxxxxxxxxx Guide for families with children receiving Proton Beam Therapy abroad Paediatric PBT Guide 2013 1 Contents Proton Beam Therapy explained (P4) What is radiotherapy? What is Proton
More informationCancer research in the Midland Region the prostate and bowel cancer projects
Cancer research in the Midland Region the prostate and bowel cancer projects Ross Lawrenson Waikato Clinical School University of Auckland MoH/HRC Cancer Research agenda Lung cancer Palliative care Prostate
More informationTeena Robinson NZRN, MN,FCNA (NZ) NP Nurse Practitioner: adult elective perioperative
Teena Robinson NZRN, MN,FCNA (NZ) NP Nurse Practitioner: adult elective perioperative Information to.. talk to our patients & families help with clinical decisions help staff allocation support new nurse
More informationHow To Choose A Pediatric Oncologist
Dr. Geoff Cuvelier MD FRCPC Pediatric Oncologist Dr. Cuvelier is a graduate of the Faculty of Medicine, University of Manitoba, and received undergraduate degrees in microbiology and sociology from the
More informationClinical Research Committee Survey on Challenges of Conducting Surgical Trials Results
Clinical Research Committee Survey on Challenges of Conducting Surgical Trials Results SURVEY RESULTS Survey population = 3500 Total responses as of 24 August 2015 = 195 Response rate = 5.6% ESSO Clinical
More informationNON CONSULTANT CAREER GRADE DOCTORS AN IMPORTANT PART OF THE PAEDIATRIC WORKFORCE
NON CONSULTANT CAREER GRADE DOCTORS AN IMPORTANT PART OF THE PAEDIATRIC WORKFORCE Background Non consultant career grade doctors (NCCGs) have traditionally formed a large part of the paediatric workforce.
More informationTransurethral Resection of Bladder Tumour (T.U.R.B.T)
Transurethral Resection of Bladder Tumour (T.U.R.B.T) Patient Information Introduction This booklet has been written to help you understand the surgery you are about to undergo. It will give you information
More informationXxxxxxxxxxxxxxxxxxxxx. A guide for adult patients receiving Proton Beam Therapy abroad. Adult PBT Guide 2013 1
Xxxxxxxxxxxxxxxxxxxxx A guide for adult patients receiving Proton Beam Therapy abroad Adult PBT Guide 2013 1 Contents Proton Beam Therapy explained (P4) What is Radiotherapy? What is Proton Beam Therapy?
More informationAnaesthetics, Pain Relief & Critical Care Services Follow-Up Study REGIONAL REPORT. Performance Review Unit
Anaesthetics, Pain Relief & Critical Care Services Follow-Up Study REGIONAL REPORT Performance Review Unit CONTENTS page I INTRODUCTION... 2 II PRE-OPERATIVEASSESSMENT... 4 III ANAESTHETIC STAFFING AND
More informationPRIMARY GLIOMA (oligodendroglioma, astrocytoma, oligodendroglioma, oligoastrocytoma, including anaplastic, gliosarcoma and glioblastoma multiforme)
Protocol for Planning and Treatment The process to be followed when a course of chemotherapy is required to treat: PRIMARY GLIOMA (oligodendroglioma, astrocytoma, oligodendroglioma, oligoastrocytoma, including
More informationClinical Commissioning Policy: Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Mesothelioma
Clinical Commissioning Policy: Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Mesothelioma Reference: NHS England B03/P/a 1 Information Reader Box (IRB) to be inserted
More informationHEALTH SPECIALIST VISITS (HSV) PROGRAMME. All Cook Islanders living healthier lives and achieving their aspirations
HEALTH SPECIALIST VISITS (HSV) PROGRAMME OUTPUTS SHORT TERM MEDIUM TERM LONG TERM GOAL OUTCOME OUTCOMES OUTCOME All Cook Islanders living healthier lives and achieving their aspirations Successful health
More informationThe New International Staging System Lung Cancer
The New International Staging System Lung Cancer Valerie W. Rusch, MD Chief, Thoracic Surgery Memorial Sloan-Kettering Cancer Center Chair, Lung and Esophagus Task Force, American Joint Commission on Cancer
More informationHow do I find the best place to get treatment for my lymphoma?
Produced November 2010 Next revision due November 2012 How do I find the best place to get treatment for my lymphoma? Introduction Fortunately this is not a question that patients with cancers of the blood
More informationLung Cancer & Mesothelioma 2011-2015
Lung Cancer & Mesothelioma 2011-2015 Annex G Mesothelioma 1. The vision for mesothelioma services is set out in the Mesothelioma Framework issued by DH on 26 February 2007 (supported by the British Thoracic
More informationIntroduction to the Gynaecological Oncology Multi-disciplinary Team (MDT) and the Macmillan Gynaecology Service
Saint Mary s Hospital Introduction to the Gynaecological Oncology Multi-disciplinary Team (MDT) and the Macmillan Gynaecology Service Information for patients What is a Macmillan Gynaecology Nurse Specialist?
More informationFact sheet 10. Borderline ovarian tumours. The difficult cases. What is borderline ovarian cancer (BOC)?
For this reason, some doctors prefer the term borderline ovarian tumour rather than borderline ovarian cancer. Fact sheet 10 Borderline ovarian tumours We, Ovacome, are a support network for people affected
More informationPaediatric Intensive Care Medicine at The Royal Children's Hospital, Melbourne
Paediatric Intensive Care Medicine at The Royal Children's Hospital, Melbourne Background The RCH PICU is an 18 bed tertiary intensive care unit that serves the state of Victoria, as well as southern New
More informationReconfiguration of Surgical, Accident and Emergency and Trauma Services in the UK
Reconfiguration of Surgical, Accident and Emergency and Trauma Services in the UK K Reconfiguration of Surgical, Accident and Emergency and Trauma Services in the UK Summary Our aim is to provide an excellent
More informationStrategic Plan. for. National Association of Medical Device Educators and Trainers NAMDET. for Period. April 2015 to March 2020
Strategic Plan for National Association of Medical Device Educators and Trainers NAMDET for Period April 2015 to March 2020 Developed by NAMDET Board Approved by: NAMDET Board and Members Issue 1, April
More informationadult services between 1 January and 31 December 2013 had an operation where the
Organisational audit: round 4 Adult services audit tool Section 1: Demographics DEM 1.1 How many IBD patients does your service manage? DEM 1.2 Is this figure: an estimate (enter e ) or from a database/register
More informationInformation for Men Diagnosed with Testicular Cancer
Patient Information Service Information for Men Diagnosed with Testicular Cancer Bristol Haematology and Oncology Centre Bristol Testicular Cancer Service Patient Information is supported by September
More informationMANCHESTER Lung Cancer Screening Program Dartmouth-Hitchcock Manchester 100 Hitchcock Way Manchester, NH 03104 (603) 695-2850
LEBANON Lung Cancer Screening Program One Medical Center Drive Lebanon, NH 03756 (603) 650-4400 (866) 966-1601 Toll-free cancer.dartmouth.edu/lungscreening MANCHESTER Lung Cancer Screening Program Dartmouth-Hitchcock
More informationQuality and Safety Programme Fractured neck of femur services
Quality and Safety Programme Fractured neck of femur services London quality standards February 2013 1 Introduction The case for change for fractured neck of femur services in London demonstrates that
More informationLead Responsibility authority and accountability see. Finish date. Commencement date. Ongoing. Ongoing. Ongoing. Ongoing. NHO Ann Doherty.
Action Plan based on recommendations arising from the report of the HIQA investigation into the provision of services to Ms A by the Health Service Executive at University Hospital Galway in relation to
More informationEthicon Travel Grant
Ethicon Travel Grant Please use typescript or CAPITAL LETTERS when filling out this form SECTION 1 PERSONAL DETAILS Title (please circle): Dr PID:11064 Surname: ABU- SERRIAH Forename(s): MUAMMAR SECTION
More informationEuropean Association of Urology Nurses Fellowship Programme
European Association of Urology Nurses Fellowship Programme Short term visit: min. 1 max. 2 weeks HOST INSTITUTION APPLICATION FORM Institutional Name Department Address Homerton University Hospital NHS
More informationQuick Facts about Appendix Cancer
Quick Facts about Appendix Cancer What is the appendix? The appendix is a pouch-like tube attached to the first part of the large intestine (cecum). The appendix is about 10 centimetres long and has no
More informationComments: Policy Accepted during 2013 Annual Review with no changes.
Health Plan Coverage Policy ARBenefits Approval: 01/01/2012 Effective Date: 01/01/2012 Revision Date: 09/18/2013 Title: Cytoreduction Surgery with Hyperthermic Intraperitoneal Chemotherapy Comments: Policy
More informationClinical Commissioning Policy: Cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Mesothelioma
Clinical Commissioning Policy: Cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Mesothelioma Reference: NHS England A08/P/c 2 NHS England INFORMATION READER BOX Directorate
More informationHealth Service Circular
Health Service Circular Series Number: HSC 2002/009 Issue Date: 04 July 2002 Review Date: 04 July 2005 Category: Public Health Status: Action sets out a specific action on the part of the recipient with
More information4. Proposed changes to Mental Health Nursing Pre-Registration Nursing
Developments in nurse education in England Summary BSMHFT employs 1319 registered nurses and 641 health care assistants 53% of the total workforce. BSMHFT works in partnership with Birmingham City University
More informationPeritoneal Carcinomatosis: Pathophysiology, Prevention, and Treatment
Peritoneal Carcinomatosis: Pathophysiology, Prevention, and Treatment Wim Ceelen, MD, PhD, FACS GI Surgery, UZ Gent KAGB 27/4/2013 Overview What is peritoneal carcinomatosis? Rationale for IP drug delivery
More informationHow To Manage A Cancer Oncology Clinic
GYNAECOLOGICAL ONCOLOGY MULTIDISCIPLINARY TEAM MEETINGS: OPERATIONAL POLICY Version 3 Policy agreed Sept 2009 (updated Jan/Feb 2013) Agreed by: SCAN gynae group 2009 Update agreed SCAN gynae group May
More informationTreatment Routes in Prostate Cancer Urological Cancers SSCRG
1 Treatment Routes in Prostate Cancer Urological Cancers SSCRG Introduction To better understand outcome measures, it is necessary to analyse what treatment pathway a patient has followed after diagnosis.
More informationMesothelioma Priority Setting Partnership. PROTOCOL November 2013
Mesothelioma Priority Setting Partnership PROTOCOL November 2013 Purpose The purpose of this protocol is to set out the aims, objectives and commitments of the Mesothelioma Priority Setting Partnership
More informationAdvances in Surgical Oncology
3-4 December 2015 Advances in Surgical Oncology 3 rd International Conference of the Medical University of Lublin 10 th anniversary of first Intraoperative Radiotherapy in Lublin 1 Scientific Chairman
More informationYour Upper GI cancer Multi-Disciplinary Team. An information guide
TO PROVIDE THE VERY BEST CARE FOR EACH PATIENT ON EVERY OCCASION Your Upper GI cancer Multi-Disciplinary Team An information guide Your Upper GI cancer Multi-Disciplinary Team Upper Gastrointestinal (GI)
More informationHow treatment is planned Giving your consent The benefits and disadvantages of treatment Second opinion
Treatment overview for lung cancer This information is an extract from the booklet Understanding lung cancer. You may find the full booklet helpful. We can send you a free copy see page 5. Contents How
More informationTreating Mesothelioma - A Quick Guide
Treating Mesothelioma - A Quick Guide Contents This is a brief summary of the information on Treating mesothelioma from CancerHelp UK. You will find more detailed information on the website. In this information
More information